BridgeBio Pharma (BBIO) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

BBIO Stock Forecast

BridgeBio Pharma stock forecast is as follows: an average price target of $47.20 (represents a 69.97% upside from BBIO’s last price of $27.77) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.

BBIO Price Target

The average price target for BridgeBio Pharma (BBIO) is $47.20 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $53.00 to $45.00. This represents a potential 69.97% upside from BBIO's last price of $27.77.

BBIO Analyst Ratings

Buy

According to 10 Wall Street analysts, BridgeBio Pharma's rating consensus is 'Buy'. The analyst rating breakdown for BBIO stock is 0 'Strong Buy' (0.00%), 9 'Buy' (90.00%), 1 'Hold' (10.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

BridgeBio Pharma Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 24, 2024	David Lebowitz	Citigroup	$45.00	$24.17	86.18%	62.05%
Oct 17, 2024	Mani Foroohar	Leerink Partners	$46.00	$26.34	74.64%	65.65%
Sep 11, 2024	Biren Amin	Piper Sandler	$46.00	$28.78	59.83%	65.65%
Sep 03, 2024	Salim Syed	Mizuho Securities	$53.00	$29.92	77.14%	90.85%
Jun 24, 2024	Danielle Brill	Raymond James	$46.00	$22.64	103.14%	65.65%
Jun 05, 2024	Kostas Biliouris	BMO Capital	$37.00	$26.93	37.42%	33.24%
Jun 05, 2024	Tiago Fauth	Wells Fargo	$58.00	$27.13	113.79%	108.86%
May 30, 2024	Paul Choi	Goldman Sachs	$50.00	$27.61	81.09%	80.05%
May 28, 2024	Eliana Merle	UBS	$47.00	$27.94	68.22%	69.25%
May 20, 2024	Raghuram Selvaraju	H.C. Wainwright	$43.00	$30.09	42.90%	54.84%
May 13, 2024	Cory Kasimov	Evercore ISI	$50.00	$28.50	75.44%	80.05%
Nov 18, 2022		J.P. Morgan	$19.00	$9.58	98.33%	-31.58%
Mar 17, 2022	Dane Leone	Raymond James	$17.00	$10.76	57.99%	-38.78%

The latest BridgeBio Pharma stock forecast, released on Oct 24, 2024 by David Lebowitz from Citigroup, set a price target of $45.00, which represents a 86.18% increase from the stock price at the time of the forecast ($24.17), and a 62.05% increase from BBIO last price ($27.77).

BridgeBio Pharma Price Target by Period

	1M	3M	12M
# Anlaysts	-	2	11
Avg Price Target	-	$45.50	$47.36
Last Closing Price	$27.77	$27.77	$27.77
Upside/Downside	-100.00%	63.85%	70.54%

In the current month, the average price target of BridgeBio Pharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to BridgeBio Pharma's last price of $27.77. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 24, 2024	Citigroup	Buy	Buy	Hold
Oct 02, 2024	Oppenheimer		Perform	Initialise
Sep 24, 2024	BMO Capital	Market Perform	Market Perform	Hold
Sep 11, 2024	Piper Sandler	Overweight	Overweight	Hold
Sep 04, 2024	Piper Sandler		Overweight	Initialise
Sep 03, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 24, 2024	Raymond James	Outperform	Outperform	Hold
Jun 24, 2024	Evercore ISI	Outperform	Outperform	Hold
Jun 10, 2024	Cowen & Co.	Buy	Buy	Hold
Jun 05, 2024	BMO Capital	Outperform	Outperform	Hold
Jun 05, 2024	Wells Fargo	Overweight	Overweight	Hold
May 30, 2024	Citigroup	Buy	Buy	Hold
May 30, 2024	Goldman Sachs	Buy	Buy	Hold
May 28, 2024	UBS	Buy	Buy	Hold
May 20, 2024	H.C. Wainwright	Buy	Buy	Hold
May 13, 2024	Evercore ISI		Outperform	Initialise
Feb 06, 2023	Cowen & Co.		Outperform	Initialise
Mar 17, 2022	Raymond James	Outperform	Outperform	Hold

BridgeBio Pharma's last stock rating was published by Citigroup on Oct 24, 2024. The company gave BBIO a "Buy" rating, the same as its previous rate.

BridgeBio Pharma Financial Forecast

BridgeBio Pharma Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$4.09M	$1.64M	$1.83M	$1.87M	$338.00K	$73.75M	$1.69M	$12.89M	$2.34M	$54.02M	$462.00K	$122.00K	$8.13M
Avg Forecast	$126.70M	$111.30M	$136.50M	$72.60M	$55.11M	$37.85M	$30.32M	$44.07M	$3.05M	$1.68M	$3.96M	$7.26M	$4.55M	$3.62M	$2.99M	$3.23M	$4.52M	$4.09M	$27.19M	$4.70M	$21.56M	$15.80M	$28.49M	$27.51M	$16.93M	$10.75M
High Forecast	$647.12M	$568.47M	$697.18M	$370.81M	$281.46M	$193.34M	$154.87M	$83.99M	$11.25M	$8.56M	$3.96M	$7.26M	$7.30M	$3.62M	$15.29M	$16.50M	$23.11M	$4.09M	$27.19M	$4.70M	$21.56M	$15.80M	$28.49M	$27.51M	$16.93M	$10.75M
Low Forecast	$9.80M	$8.61M	$10.56M	$5.62M	$4.26M	$2.93M	$2.35M	$4.95M	$272.74K	$129.64K	$3.96M	$7.26M	$995.98K	$3.62M	$231.60K	$250.04K	$350.11K	$4.09M	$27.19M	$4.70M	$21.56M	$15.80M	$28.49M	$27.51M	$16.93M	$10.75M
# Analysts	4	4	4	4	2	2	2	6	10	5	2	2	4	9	7	4	3	7	4	3	4	7	4	4	4	6
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.13%	0.55%	0.57%	0.41%	0.08%	2.71%	0.36%	0.60%	0.15%	1.90%	0.02%	0.01%	0.76%

BridgeBio Pharma's average Quarter revenue forecast for Dec 23 based on 4 analysts is $4.55M, with a low forecast of $995.98K, and a high forecast of $7.30M. BBIO's average Quarter revenue forecast represents a 11.18% increase compared to the company's last Quarter revenue of $4.09M (Sep 23).

BridgeBio Pharma EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	4	4	4	4	2	2	2	6	10	5	2	2	4	9	7	4	3	7	4	3	4	7	4	4	4	6
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-157.69M	$-146.10M	$-117.61M	$-112.89M	$-113.71M	$27.70M	$-156.44M	$-130.52M	$-144.60M	$-82.82M	$-151.98M	$-109.02M	$-104.93M
Avg Forecast	$-126.70M	$-111.30M	$-136.50M	$-72.60M	$-55.11M	$-37.85M	$-30.32M	$-44.07M	$-3.05M	$-1.68M	$-3.96M	$-119.34M	$-4.55M	$-3.62M	$-2.99M	$-127.64M	$-120.47M	$-4.09M	$-27.19M	$-136.51M	$-21.56M	$-15.80M	$-28.49M	$-67.77M	$-16.93M	$-10.75M
High Forecast	$-9.80M	$-8.61M	$-10.56M	$-5.62M	$-4.26M	$-2.93M	$-2.35M	$-4.95M	$-272.74K	$-129.64K	$-3.96M	$-95.47M	$-995.98K	$-3.62M	$-231.60K	$-102.11M	$-96.37M	$-4.09M	$-27.19M	$-109.21M	$-21.56M	$-15.80M	$-28.49M	$-54.22M	$-16.93M	$-10.75M
Low Forecast	$-647.12M	$-568.47M	$-697.18M	$-370.81M	$-281.46M	$-193.34M	$-154.87M	$-83.99M	$-11.25M	$-8.56M	$-3.96M	$-143.21M	$-7.30M	$-3.62M	$-15.29M	$-153.17M	$-144.56M	$-4.09M	$-27.19M	$-163.81M	$-21.56M	$-15.80M	$-28.49M	$-81.33M	$-16.93M	$-10.75M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	43.51%	48.81%	0.92%	0.94%	27.83%	-1.02%	1.15%	6.05%	9.15%	2.91%	2.24%	6.44%	9.76%

7 analysts predict BBIO's average Quarter EBITDA for Sep 22 to be $-4.09M, with a high of $-4.09M and a low of $-4.09M. This is -114.75% lower than BridgeBio Pharma's previous annual EBITDA (Jun 22) of $27.70M.

BridgeBio Pharma Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	4	4	4	4	2	2	2	6	10	5	2	2	4	9	7	4	3	7	4	3	4	7	4	4	4	6
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-177.00M	$-157.90M	$-176.85M	$-155.97M	$-148.42M	$59.37M	$-246.71M	$-167.42M	$-155.94M	$-96.35M	$-163.08M	$-119.98M	$-115.86M
Avg Forecast	$-134.78M	$-142.33M	$-131.96M	$-153.64M	$-174.42M	$-186.73M	$-190.59M	$-179.68M	$-213.72M	$-189.14M	$-188.16M	$-134.57M	$-163.79M	$-149.56M	$-150.58M	$-143.93M	$-135.84M	$-181.61M	$-104.42M	$-153.93M	$-165.43M	$-171.56M	$-182.26M	$-72.72M	$-161.35M	$-168.41M
High Forecast	$26.88M	$28.38M	$26.31M	$30.64M	$34.78M	$37.24M	$38.01M	$-149.40M	$-174.86M	$37.72M	$37.52M	$-107.66M	$-137.93M	$-116.33M	$30.03M	$-115.14M	$-108.67M	$-181.61M	$-104.42M	$-123.15M	$-165.43M	$-171.56M	$-182.26M	$-58.18M	$-161.35M	$-168.41M
Low Forecast	$-854.51M	$-902.31M	$-836.58M	$-974.02M	$-1.11B	$-1.18B	$-1.21B	$-216.02M	$-252.58M	$-1.20B	$-1.19B	$-161.49M	$-200.00M	$-184.64M	$-954.65M	$-172.71M	$-163.01M	$-181.61M	$-104.42M	$-184.72M	$-165.43M	$-171.56M	$-182.26M	$-87.27M	$-161.35M	$-168.41M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.18%	1.05%	1.23%	1.15%	0.82%	-0.57%	1.60%	1.01%	0.91%	0.53%	2.24%	0.74%	0.69%

BridgeBio Pharma's average Quarter net income forecast for Sep 22 is $-181.61M, with a range of $-181.61M to $-181.61M. BBIO's average Quarter net income forecast represents a -405.91% decrease compared to the company's last Quarter net income of $59.37M (Jun 22).

BridgeBio Pharma SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	4	4	4	4	2	2	2	6	10	5	2	2	4	9	7	4	3	7	4	3	4	7	4	4	4	6
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$35.78M	$36.12M	$31.11M	$31.86M	$31.19M	$36.43M	$43.71M	$54.75M	$46.08M	$45.97M	$45.41M	$37.44M	$36.02M
Avg Forecast	$1.03B	$907.66M	$1.11B	$592.06M	$449.40M	$308.70M	$247.28M	$359.36M	$24.91M	$13.66M	$32.30M	$59.20M	$37.09M	$29.56M	$24.41M	$26.35M	$36.90M	$33.33M	$221.73M	$38.29M	$175.85M	$128.85M	$232.30M	$20.25M	$138.07M	$87.67M
High Forecast	$5.28B	$4.64B	$5.69B	$3.02B	$2.30B	$1.58B	$1.26B	$684.93M	$91.75M	$69.79M	$32.30M	$59.20M	$59.56M	$29.56M	$124.67M	$134.60M	$188.46M	$33.33M	$221.73M	$38.29M	$175.85M	$128.85M	$232.30M	$24.30M	$138.07M	$87.67M
Low Forecast	$79.95M	$70.23M	$86.13M	$45.81M	$34.77M	$23.89M	$19.13M	$40.39M	$2.22M	$1.06M	$32.30M	$59.20M	$8.12M	$29.56M	$1.89M	$2.04M	$2.86M	$33.33M	$221.73M	$38.29M	$175.85M	$128.85M	$232.30M	$16.20M	$138.07M	$87.67M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.21%	1.48%	1.18%	0.86%	0.94%	0.16%	1.14%	0.31%	0.36%	0.20%	2.24%	0.27%	0.41%

BridgeBio Pharma's average Quarter SG&A projection for Dec 23 is $37.09M, based on 4 Wall Street analysts, with a range of $8.12M to $59.56M. The forecast indicates a 3.67% rise compared to BBIO last annual SG&A of $35.78M (Sep 23).

BridgeBio Pharma EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	4	4	4	4	2	2	2	6	10	5	2	2	4	9	7	4	3	7	4	3	4	7	4	4	4	6
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.00	$-0.00	$-1.16	$-1.04	$-1.00	$0.40	$-1.69	$-1.15	$-1.06	$-0.66	$-1.18	$-1.01	$-0.98
Avg Forecast	$-0.71	$-0.76	$-0.70	$-0.81	$-0.93	$-0.99	$-1.01	$-0.95	$-1.13	$-1.00	$-1.00	$-0.74	$-0.87	$-0.79	$-0.80	$-0.82	$-0.84	$-0.97	$-0.56	$-1.09	$-0.88	$-0.91	$-0.97	$-0.75	$-0.86	$-0.90
High Forecast	$0.14	$0.15	$0.14	$0.16	$0.18	$0.20	$0.20	$-0.79	$-0.93	$0.20	$0.20	$0.15	$-0.73	$-0.62	$0.16	$0.16	$0.17	$-0.97	$-0.56	$-1.09	$-0.88	$-0.91	$-0.97	$-0.75	$-0.86	$-0.90
Low Forecast	$-4.53	$-4.79	$-4.44	$-5.17	$-5.87	$-6.28	$-6.41	$-1.15	$-1.34	$-6.36	$-6.33	$-4.67	$-1.06	$-0.98	$-5.06	$-5.21	$-5.31	$-0.97	$-0.56	$-1.09	$-0.88	$-0.91	$-0.97	$-0.75	$-0.86	$-0.90
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00%	0.00%	1.41%	1.24%	1.03%	-0.72%	1.56%	1.30%	1.16%	0.68%	1.57%	1.17%	1.09%

According to 7 Wall Street analysts, BridgeBio Pharma's projected average Quarter EPS for Sep 22 is $-0.97, with a low estimate of $-0.97 and a high estimate of $-0.97. This represents a -342.03% decrease compared to BBIO previous annual EPS of $0.40 (Jun 22).

BridgeBio Pharma Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
INZY	Inozyme Pharma	$2.94	$16.00	444.22%	Buy
XFOR	X4 Pharmaceuticals	$0.74	$3.67	395.95%	Buy
ABOS	Acumen Pharmaceuticals	$1.96	$7.00	257.14%	Buy
TERN	Terns Pharmaceuticals	$6.80	$18.67	174.56%	Buy
APLS	Apellis Pharmaceuticals	$34.53	$70.80	105.04%	Buy
AMLX	Amylyx Pharmaceuticals	$4.28	$8.25	92.76%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
BBIO	BridgeBio Pharma	$27.82	$47.20	69.66%	Buy
BPMC	Blueprint Medicines	$96.48	$122.60	27.07%	Buy
KRYS	Krystal Biotech	$169.04	$210.33	24.43%	Buy
MDGL	Madrigal Pharmaceuticals	$306.08	$315.75	3.16%	Buy
PTCT	PTC Therapeutics	$47.02	$48.00	2.08%	Hold

BBIO Forecast FAQ

Is BridgeBio Pharma a good buy?

Yes, according to 10 Wall Street analysts, BridgeBio Pharma (BBIO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 90.00% of BBIO's total ratings.

What is BBIO's price target?

BridgeBio Pharma (BBIO) average price target is $47.2 with a range of $45 to $53, implying a 69.97% from its last price of $27.77. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will BridgeBio Pharma stock go up soon?

According to Wall Street analysts' prediction for BBIO stock, the company can go up by 69.97% (from the last price of $27.77 to the average price target of $47.2), up by 90.85% based on the highest stock price target, and up by 62.05% based on the lowest stock price target.

Can BridgeBio Pharma stock reach $40?

BBIO's average twelve months analyst stock price target of $47.2 supports the claim that BridgeBio Pharma can reach $40 in the near future.

What are BridgeBio Pharma's analysts' financial forecasts?

BridgeBio Pharma's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $167.35M (high $713.66M, low $14.49M), average EBITDA is $-167M (high $-14.492M, low $-714M), average net income is $-731M (high $-39.374M, low $-3.714B), average SG&A $1.36B (high $5.82B, low $118.18M), and average EPS is $-3.88 (high $-0.209, low $-19.702). BBIO's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $447.1M (high $2.28B, low $34.6M), average EBITDA is $-447M (high $-34.595M, low $-2.284B), average net income is $-563M (high $112.21M, low $-3.567B), average SG&A $3.65B (high $18.62B, low $282.13M), and average EPS is $-2.985 (high $0.595, low $-18.924).

Did the BBIO's actual financial results beat the analysts' financial forecasts?

Based on BridgeBio Pharma's last annual report (Dec 2022), the company's revenue was $77.65M, beating the average analysts forecast of $40.5M by 91.74%. Apple's EBITDA was $-354M, beating the average prediction of $-288M by 22.70%. The company's net income was $-494M, missing the average estimation of $-576M by -14.21%. Apple's SG&A was $143.19M, missing the average forecast of $330.25M by -56.64%. Lastly, the company's EPS was $-3.35, missing the average prediction of $-3.449 by -2.88%. In terms of the last quarterly report (Sep 2023), BridgeBio Pharma's revenue was $4.09M, beating the average analysts' forecast of $3.62M by 12.87%. The company's EBITDA was $-158M, beating the average prediction of $-3.625M by 4250.58%. BridgeBio Pharma's net income was $-177M, beating the average estimation of $-150M by 18.34%. The company's SG&A was $35.78M, beating the average forecast of $29.56M by 21.04%. Lastly, the company's EPS was $-0.0011, missing the average prediction of $-0.793 by -99.86%